Advancing ASO therapies from development to implementation
A novel application of antisense oligonucleotide (ASO) technology, developed to treat a single patient, adds to the growing number of ‘personalized’ therapies for rare diseases; but pathways to implementation and access are urgently needed.
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 September 2024
|
| In: |
Nature medicine
Year: 2024, Jahrgang: 30, Heft: 10, Pages: 2725-2726 |
| ISSN: | 1546-170X |
| DOI: | 10.1038/s41591-024-03217-x |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41591-024-03217-x Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41591-024-03217-x 
|
| Verfasserangaben: | Rebecca Schuele, Matthis Synofzik, Holm Graessner & Annemieke Aartsma-Rus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1922073571 | ||
| 003 | DE-627 | ||
| 005 | 20250717005645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250410s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-024-03217-x |2 doi | |
| 035 | |a (DE-627)1922073571 | ||
| 035 | |a (DE-599)KXP1922073571 | ||
| 035 | |a (OCoLC)1528044485 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 32 |2 sdnb | ||
| 100 | 1 | |a Schüle-Freyer, Rebecca |d 1975- |e VerfasserIn |0 (DE-588)137544472 |0 (DE-627)695848283 |0 (DE-576)30411118X |4 aut | |
| 245 | 1 | 0 | |a Advancing ASO therapies from development to implementation |c Rebecca Schuele, Matthis Synofzik, Holm Graessner & Annemieke Aartsma-Rus |
| 264 | 1 | |c 13 September 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.04.2025 | ||
| 520 | |a A novel application of antisense oligonucleotide (ASO) technology, developed to treat a single patient, adds to the growing number of ‘personalized’ therapies for rare diseases; but pathways to implementation and access are urgently needed. | ||
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Neurological disorders | |
| 700 | 1 | |a Synofzik, Matthis |d 1979- |e VerfasserIn |0 (DE-588)136837247 |0 (DE-627)587805188 |0 (DE-576)301302022 |4 aut | |
| 700 | 1 | |a Graessner, Holm |e VerfasserIn |0 (DE-588)1156559421 |0 (DE-627)1019354224 |0 (DE-576)502247762 |4 aut | |
| 700 | 1 | |a Aartsma-Rus, Annemieke |e VerfasserIn |0 (DE-588)1159167427 |0 (DE-627)1021159050 |0 (DE-576)504744232 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d [New York, NY] : Springer Nature, 1995 |g 30(2024), 10, Seite 2725-2726 |h Online-Ressource |w (DE-627)301511640 |w (DE-600)1484517-9 |w (DE-576)288571274 |x 1546-170X |7 nnas |a Advancing ASO therapies from development to implementation |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:10 |g pages:2725-2726 |g extent:2 |a Advancing ASO therapies from development to implementation |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41591-024-03217-x |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41591-024-03217-x |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250410 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 137544472 |a Schüle-Freyer, Rebecca |m 137544472:Schüle-Freyer, Rebecca |d 910000 |d 911100 |e 910000PS137544472 |e 911100PS137544472 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1922073571 |e 4699852998 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Rebecca Schuele, Matthis Synofzik, Holm Graessner & Annemieke Aartsma-Rus"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1922073571","title":[{"title":"Advancing ASO therapies from development to implementation","title_sort":"Advancing ASO therapies from development to implementation"}],"origin":[{"dateIssuedDisp":"13 September 2024","dateIssuedKey":"2024"}],"id":{"doi":["10.1038/s41591-024-03217-x"],"eki":["1922073571"]},"relHost":[{"recId":"301511640","disp":"Advancing ASO therapies from development to implementationNature medicine","title":[{"title":"Nature medicine","title_sort":"Nature medicine"}],"part":{"year":"2024","text":"30(2024), 10, Seite 2725-2726","pages":"2725-2726","extent":"2","issue":"10","volume":"30"},"pubHistory":["1.1995 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 24. Juli 2018"],"origin":[{"publisherPlace":"[New York, NY] ; New York, NY","publisher":"Springer Nature ; Nature America Inc.","dateIssuedKey":"2017","dateIssuedDisp":"2017-"}],"id":{"eki":["301511640"],"issn":["1546-170X"],"zdb":["1484517-9"]}}],"physDesc":[{"noteIll":"Illustrationen","extent":"2 S."}],"person":[{"roleDisplay":"VerfasserIn","family":"Schüle-Freyer","given":"Rebecca","role":"aut","display":"Schüle-Freyer, Rebecca"},{"roleDisplay":"VerfasserIn","family":"Synofzik","given":"Matthis","display":"Synofzik, Matthis","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Graessner","role":"aut","display":"Graessner, Holm","given":"Holm"},{"display":"Aartsma-Rus, Annemieke","role":"aut","given":"Annemieke","roleDisplay":"VerfasserIn","family":"Aartsma-Rus"}],"note":["Gesehen am 10.04.2025"]} | ||
| SRT | |a SCHUELEFREADVANCINGA1320 | ||